Translate Bio Inc TBIO:NASDAQ

RT Quote | Last NASDAQ LS, VOL From CTA | USD
after hours iconAfter Hours: Last | 4:00 PM EST
21.45UNCH (UNCH)
Volume
5,536
Close
21.45quote price arrow down-0.53 (-2.41%)
Volume
805,943
52 week range
6.80 - 34.64

...

Loading . . .

KEY STATS

  • Open22.01
  • Day High22.21
  • Day Low21.41
  • Prev Close21.98
  • 52 Week High34.64
  • 52 Week High Date02/08/21
  • 52 Week Low6.80
  • 52 Week Low Date03/09/20
  • Market Cap1.613B
  • Shares Out75.21M
  • 10 Day Average Volume0.92M
  • Dividend-
  • Dividend Yield-
  • Beta0.86
  • 1 Year % Change180.03

RATIOS/PROFITABILITY

  • EPS (TTM)-1.11
  • P/E (TTM)-19.32
  • Fwd P/E (NTM)-36.29
  • EBITDA (MRQ)-58.213M
  • ROE (MRQ)-23.49%
  • Revenue (MRQ)91.31M
  • Gross Margin (MRQ)-
  • Net Margin (MRQ)-70.38%
  • Debt To Equity (MRQ)0.00%

EVENTS

  • Earnings Date05/09/2021
  • Ex Div Date-
  • Div Amount-
  • Split Date-
  • Split Factor-

Latest Translate Bio Inc News

There is no recent news for this security.

Latest TBIO News From Our Partners

QUOTE FINDER

Profile

MORE
Translate Bio, Inc. is a messenger RNA, or mRNA, therapeutics company. The Company is developing medicines to treat diseases caused by protein or gene dysfunction. The Company is using its proprietary mRNA therapeutic platform, or MRT platform, and it create mRNA that encodes functional proteins. The mRNA is delivered to the target cell where the cell’s own machinery recognizes it and translates it, restoring or augmenting protein function to treat or prevent disease. The MRT...
Daniel Lynch
Chairman
Ronald Renaud Jr.
President
Paul Burgess J.D.
Chief Operating Officer
Frank DeRosa Ph.D.
Chief Technology Officer
Robert Prentiss
Chief Accounting Officer
Address
29 Hartwell Ave
Lexington, MA
02421-3102
United States